Results 11 to 20 of about 1,268 (176)

Efgartigimod in the treatment of Guillain-Barré syndrome: case report [PDF]

Frontiers in Immunology
Guillain–Barré syndrome (GBS) is a rare neurological disorder characterized by muscle weakness and paralysis. Although the exact etiology remains unclear, the current standard treatments include intravenous immunoglobulin (IVIG) and plasma exchange (PLEX)
Min Deng, Zhaohong Kong, Yan Wang, Xufeng Wang, Tao Li   +4 more
doaj   +5 more sources

Efgartigimod in refractory autoimmune myasthenia gravis [PDF]

Muscle and Nerve
AbstractIntroduction/AimsEfgartigimod, a neonatal Fc‐receptor inhibitor, has recently been approved as treatment for myasthenia gravis (MG). In this retrospective cohort study, we aimed to systematically assess short‐ and long‐term effectiveness of efgartigimod in patients with refractory MG.MethodsSixteen patients with refractory autoimmune ...
Linda Remijn-Nelissen, Martijn R Tannemaat, Annabel M Ruiter   +2 more
exaly   +6 more sources

Efgartigimod: First Approval [PDF]

Drugs, 2022
Efgartigimod (efgartigimod alfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti ...
Young-A Heo (5060039)
openaire   +4 more sources

Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes [PDF]

Therapeutic Advances in Neurological Disorders
Background: Efgartigimod is an approved biologic for generalized myasthenia gravis (gMG), which is an autoimmune disease and can potentially be life-threatening. However, the therapeutic response to efgartigimod among the acetylcholine receptor gMG (AChR-
Zongtai Wu, Lei Jin, Zhang-Yu Zou
exaly   +4 more sources

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy [PDF]

Frontiers in Neurology
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients ...
Qiqi Peng, Xiaoping Yao, Sheng Chen, Xiaofeng Li, Feifei Lin, Zhangyu Zou   +5 more
doaj   +3 more sources

Efgartigimod combined with steroids as a fast-acting therapy for myasthenic crisis: a case report [PDF]

BMC Neurology
Background Generalized myasthenia gravis (gMG) can be managed with acetylcholinesterase inhibitors (AChEis; e.g., pyridostigmine), corticosteroids, other immunosuppressive drugs (e.g., tacrolimus), and their combinations. Intravenous immunoglobulin (IVIg)
Hiroya Ohara, Naoya Kikutsuji, Naohiko Iguchi, Masako Kinoshita   +3 more
doaj   +2 more sources

Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants [PDF]

Drugs in R&D
Efgartigimod, a human immunoglobulin G (IgG)1-derived Fc fragment targeting the neonatal Fc receptor, has been developed into intravenous (IV) and subcutaneous (SC) formulations for treating generalized myasthenia gravis (gMG) and other autoimmune diseases. Data in the Chinese population were not available to date, and while both formulations have been
Shan Jing, Yu Zhang, Yang Lin, Xiaowen Gu, Jing Liu, Antonio Guglietta, Jan Noukens, Tonke Van Bragt, Lina Wang, Jiajia Chen, Harald Reinhart, Xia Pu   +11 more
openaire   +4 more sources

Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeys [PDF]

Journal of Immunotoxicology
Efgartigimod is a human IgG1 antibody Fc fragment that reduces IgG levels through neonatal Fc receptor blockade. This study evaluated whether efgartigimod affects the generation of T-cell-dependent antibodies and cellular immune responses to keyhole ...
Ornella Binazon, Mario Cocco, Daniel Thwaites, Christopher Cooper, Mahan Moshir, Peter Vanhoenacker, Dieter Defever, Ariëlla Van de Sompel, Sophie Steeland, Gwenda Pynaert, Peter Ulrichts, Judith Baumeister   +11 more
doaj   +2 more sources

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus [PDF]

Frontiers in Immunology, 2022
BackgroundImmunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal ...
Maud Maho-Vaillant, Maud Maho-Vaillant, Magdalena Sips, Marie-Laure Golinski, Marie-Laure Golinski, Gestur Vidarsson, Matthias Goebeler, Johanna Stoevesandt, Zsuzsanna Bata-Csörgő, Bianca Balbino, Peter Verheesen, Pascal Joly, Michael Hertl, Sébastien Calbo   +13 more
doaj   +5 more sources

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation [PDF]

Frontiers in Neurology
BackgroundThe prevalence of patients positive for muscle-specific kinase antibody (hereafter, MuSK-Ab) accounts for 5–8% of all myasthenia gravis (MG) cases.
Fangyi Shi, Fangyi Shi, Fangyi Shi, Jiaxin Chen, Jiaxin Chen, Jiaxin Chen, Li Feng, Li Feng, Li Feng, Rong Lai, Rong Lai, Rong Lai, Hongyan Zhou, Hongyan Zhou, Hongyan Zhou, Xunsha Sun, Xunsha Sun, Xunsha Sun, Cunzhou Shen, Cunzhou Shen, Cunzhou Shen, Jiezhen Feng, Jiezhen Feng, Jiezhen Feng, Huiyu Feng, Huiyu Feng, Huiyu Feng, Haiyan Wang, Haiyan Wang, Haiyan Wang   +29 more
doaj   +3 more sources